Introduction
The global overdose crisis continues to claim lives at an alarming rate. The U.S. Centers for Disease Control and Prevention (CDC) reported over 107,000 drug overdose deaths in the United States in 2024, with synthetic opioids — primarily fentanyl — involved in approximately 70% of fatalities. The World Health Organization (WHO) estimates that approximately 500,000 deaths worldwide are attributable to drug use annually, with opioids accounting for the majority. Beyond opioids, toxicological emergencies encompass a broad spectrum of substances — carbon monoxide, organophosphates, methanol, heavy metals, and prescription medications — each presenting unique detection challenges. A critical factor in overdose survival is time to intervention: opioid-induced respiratory depression can progress to cardiac arrest within 4–6 minutes of onset, and naloxone administered within this window is highly effective. Medical wearables capable of continuous physiological monitoring — particularly respiratory rate, oxygen saturation, and heart rate — offer the potential to detect overdose events in real time, automatically alert emergency responders, and dramatically reduce time to intervention. This B2B OEM guide examines the technology, clinical evidence, and manufacturing considerations for wearable toxicology monitoring devices.
The Overdose Detection Challenge
The fundamental challenge in overdose detection is that the victim is typically incapacitated and unable to call for help. Unlike cardiac events, where the patient may experience warning symptoms (chest pain, shortness of breath) and have time to seek assistance, opioid overdose is characterized by rapid loss of consciousness and respiratory depression. The person most likely to be present during an overdose is another person who uses drugs — and that person may be reluctant to call emergency services due to fear of legal consequences, even in jurisdictions with Good Samaritan laws.
A wearable overdose detection system addresses this challenge by automating the detection and alerting process. The device continuously monitors physiological parameters that change predictably during overdose:
– Respiratory rate: The most critical parameter. Opioid-induced respiratory depression causes respiratory rate to drop below 8 breaths per minute (normal: 12–20), progressing to apnea
– Oxygen saturation (SpO2): Declines as respiratory depression impairs gas exchange, typically falling below 90% (normal: 95–100%) within minutes of overdose onset
– Heart rate: Initially increases due to hypoxia-induced sympathetic activation, then progressively declines as myocardial oxygen deprivation leads to bradycardia
– Motion/activity: Absence of movement — the person becomes unconscious and motionless — combined with respiratory depression provides a high-specificity overdose signature
Technology Platforms for Toxicology Monitoring
Pulse Oximetry and Respiratory Rate Monitoring
The most straightforward approach to overdose detection combines continuous pulse oximetry with respiratory rate monitoring derived from photoplethysmography (PPG). PPG-based respiratory rate estimation — which extracts the respiratory modulation of the PPG waveform — has been validated against capnography (the gold standard for respiratory monitoring) with mean absolute errors of 1–2 breaths per minute in multiple clinical studies.
A 2025 systematic review in Anesthesia & Analgesia examined 14 studies of wearable respiratory monitoring and concluded that PPG-derived respiratory rate is sufficiently accurate for clinical decision support, with the caveat that motion artifacts and low perfusion states (common in overdose) can degrade signal quality. Multi-wavelength PPG and accelerometer-based motion compensation improve robustness under these challenging conditions.
Capnography (End-Tidal CO2)
Capnography — the measurement of carbon dioxide in exhaled breath — is the gold standard for respiratory monitoring and is standard of care in operating rooms and intensive care units. Miniaturized mainstream and sidestream capnography sensors are now available in wearable form factors, typically integrated into a nasal cannula or face mask. While more accurate than PPG-based respiratory monitoring, capnography wearables are less comfortable for continuous use and are better suited for supervised settings (e.g., post-operative monitoring, medically supervised consumption sites) than for unsupervised community use.
Multi-Modal Sensor Fusion
The highest accuracy for overdose detection is achieved through multi-modal sensor fusion. A 2026 study in Lancet Digital Health demonstrated that an AI system combining PPG, accelerometry, and electrodermal activity (EDA) data achieved 94% sensitivity and 96% specificity for detecting opioid-induced respiratory depression in a supervised clinical setting. The system’s ability to distinguish between sleep (where respiratory rate may naturally decrease) and overdose (where respiratory depression is accompanied by motionlessness and abnormal EDA patterns) was critical to minimizing false alarms.
The study also found that AI-based screening for opioid use disorder reduced 30-day readmission odds by 47% compared with standard provider consultation, illustrating the potential of wearable monitoring to significantly change patient outcomes.
Clinical and Public Health Applications
Harm Reduction and Community-Based Overdose Prevention
Supervised consumption sites (SCS) — also known as overdose prevention centers — have been established in Canada, Australia, and several European countries, with the first U.S. sites opening in New York City in 2021. In these settings, staff visually monitor clients for signs of overdose and intervene with oxygen and naloxone as needed. Wearable monitoring could augment visual observation — particularly during periods of high client volume — and could extend monitoring to unsupervised settings such as supportive housing and post-incarceration transitional programs.
The National Institute on Drug Abuse (NIDA) has identified wearable overdose detection as a priority research area, funding multiple studies through its “Saving Lives: Wearable Sensors for Overdose Detection and Intervention” initiative.
Post-Operative Opioid Monitoring
The transition from hospital to home after surgery is a period of elevated overdose risk. Patients receive opioid prescriptions for post-operative pain management and may take more medication than prescribed — particularly if pain is inadequately controlled or if they are opioid-naive and unaware of dose-response relationships. A wearable monitor worn during the first 48–72 hours post-discharge — the highest-risk period for opioid-induced respiratory depression — could detect overdose events and alert caregivers or emergency services.
The Anesthesia Patient Safety Foundation (APSF) has recommended continuous monitoring of all patients receiving parenteral opioids, and the Centers for Medicare & Medicaid Services (CMS) has incorporated respiratory monitoring into quality measures for post-operative care.
Occupational Toxicology
Workers in chemical manufacturing, agriculture, mining, and first response are at risk of exposure to toxic substances including carbon monoxide, hydrogen sulfide, organophosphate pesticides, and industrial solvents. The U.S. Occupational Safety and Health Administration (OSHA) sets permissible exposure limits (PELs) for hundreds of substances, but compliance monitoring is typically based on periodic air sampling rather than continuous biological monitoring.
Wearable toxicology monitors — incorporating electrochemical gas sensors for airborne toxins and PPG-based monitoring for physiological effects — could provide real-time exposure assessment and early warning of toxic effects. For carbon monoxide, which binds to hemoglobin with 200–250 times the affinity of oxygen and produces characteristic changes in pulse oximetry readings, multi-wavelength oximetry can distinguish between oxyhemoglobin and carboxyhemoglobin, providing a direct measure of CO exposure.
Environmental Toxicology and Poison Control
Community exposure to environmental toxins — including lead in drinking water, mercury in seafood, and air pollution — is a major public health concern. While wearable sensors cannot directly measure blood levels of most toxins, they can monitor physiological parameters that change in response to toxic exposure. For example, lead toxicity causes peripheral neuropathy that may manifest as changes in heart rate variability, and organophosphate poisoning causes characteristic changes in heart rate (bradycardia followed by tachycardia) and respiratory pattern.
Integration with poison control center systems — the U.S. network of 55 poison centers that receive over 2 million calls annually — could enable wearable data to inform triage decisions and treatment recommendations.
OEM Manufacturing Considerations
Clinical Validation in Target Populations
Wearable overdose detection devices must be validated in the populations where they will be deployed. This presents unique challenges: individuals who use opioids may be difficult to recruit for clinical studies, and creating controlled overdose scenarios for validation purposes is ethically complex. Alternative validation strategies include:
– Supervised opioid administration studies: Recruiting individuals receiving medically supervised opioids (e.g., in pain management or addiction treatment settings) to establish the relationship between opioid dose and physiological changes
– Retrospective analysis: Using data from hospital rapid response teams and code blue events to identify the physiological signatures of overdose in clinical monitoring data
– Simulated overdose: Using breath-hold protocols and hypoxic gas mixtures to simulate the respiratory depression of overdose in healthy volunteers
Alarm Fatigue and False Alarm Management
The bane of all monitoring systems is alarm fatigue — the desensitization that occurs when clinicians or caregivers are exposed to frequent false alarms. For community-based overdose detection, false alarms that trigger emergency services responses are not merely inconvenient — they waste first responder resources and may erode trust in the technology. The system must balance sensitivity (detecting true overdoses) against specificity (minimizing false alarms) through:
– Multi-parameter confirmation: Requiring simultaneous abnormalities in respiratory rate, SpO2, and motion before triggering an alert
– Escalating alert hierarchy: Starting with a haptic prompt to the wearer (“Are you okay? Tap to confirm”), escalating to caregiver notification if no response, and finally to emergency services
– Contextual awareness: Recognizing that physiological changes during sleep, exercise, or illness may mimic overdose signatures and adjusting alert thresholds accordingly
Regulatory Considerations
The FDA’s 2025 guidance on Clinical Decision Support (CDS) Software is relevant to wearable overdose detection: devices that “inform” clinical decisions (e.g., notifying a caregiver of respiratory depression) may qualify for enforcement discretion, while devices that “drive” clinical decisions (e.g., automatically administering naloxone via an integrated pump) would require premarket approval. The FDA’s Breakthrough Device Designation may be available for devices that address the opioid crisis, given the public health urgency.
Stigma and User Acceptance
Wearable overdose detection devices must navigate the stigma associated with drug use. Devices that are visibly identifiable as “overdose monitors” may be rejected by the target population. Designs that resemble consumer wearables (smartwatches, fitness trackers) and serve dual purposes (general health monitoring in addition to overdose detection) are more likely to achieve adoption. Community engagement — involving people who use drugs in the design and testing process — is essential for developing devices that are acceptable, usable, and effective in real-world settings.
Conclusion
The overdose crisis demands innovative solutions that extend beyond traditional public health and law enforcement approaches. Medical wearables for toxicology monitoring — capable of detecting opioid-induced respiratory depression, environmental toxin exposure, and other toxicological emergencies in real time — offer a technology-enabled pathway to reducing overdose deaths. For B2B OEM buyers, this is a market defined by urgent public health need, growing regulatory support, and technological feasibility. The devices that succeed will be those that combine clinical-grade accuracy with user-centered design that respects the dignity and autonomy of the people they are designed to protect.
Contact Geyan Technology Innovation to explore custom wearable development for toxicology monitoring and overdose detection. Our OEM/ODM services deliver multi-modal sensor platforms, AI-driven detection algorithms, and user-centered designs for harm reduction and occupational health applications.
📧 jine@xdunmedical.com | 📞 +86-13544254314